通络胶囊治疗偏头痛的临床与实验研究

认为正气不足、病理体质为偏头痛的发病基础 ,以气血失调为主 ,寒热虚实错杂是本病的基本病机。据此确立扶正固本、祛风活络、化瘀止痛的治疗原则 ,拟通络胶囊治疗偏头痛 30例 ,与太极通天液治疗 30例对照 ,结果表明 ,治疗组愈显率 83.33% ,总有效率 93.33% ,与对照组相比有显著性差别 (P<0 .0 1) ,在改善兼症方面亦优于对照组 (P<0 .0 5或 P<0 .0 1) ,并能改善患者颅内血管功能状态。动物实验表明 ,通络胶囊能提高实验动物痛阈 ,同时提高大鼠下丘脑 5 - HT及 β-内啡呔水平 ,并能改善大鼠软脑膜微循环。     

竹黄通痹胶囊治疗痛风43例

目的：为寻求一种对治疗痛风病更为有效而且服用方便的方药。方法：门诊收治的43例患,根据临床表现,化验室检查和X线摄片而确诊。每日口服“竹黄通痹胶囊”连续服用3个月。结果：43例患临床痊愈30例,有效11例,无效2例,总有效率为95．4％。结论：竹黄通痹胶囊具有清热利湿,活血通络,消肿止痛等作用,且无不良反应。     

薄层扫描法测定还五溶栓胶囊中黄芪甲苷的含量

目的 :测定还五溶栓胶囊中黄芪甲苷的含量。方法 :硅胶G薄层板 ,氯仿 -甲醇 -水 (13∶6∶2 ) 10℃以下放置过夜的下层溶液展开 ,λS=5 30nm ,λR=70 0nm。结果 :线性范围 1.92～ 9.6 0 μg ,97.4 3% ,RSD =3.4 9%。 结论 :该方法可用于还五溶栓胶囊中黄芪甲苷的含量测定     

硅凝胶型乳房假体凝胶外渗的实验研究

目的 :研究硅凝胶型乳房假体植入大鼠体内后凝胶外渗对机体的影响。方法 :取 40只健康SD雌性大鼠分成A、B、C、D 4组 ,A、B、C 3组分别植入实验用完整的硅凝胶型假体、刺破的硅凝胶型假体及生理盐水充注型假体于大鼠背侧皮下 ,D组为空白对照。术前测出血液中有机硅的浓度。 6个月后取出假体观察 ,进行假体包膜组织学检查及大鼠血液中术后有机硅的浓度测定。结果 :A、B、C 3组纤维包膜组织学特征无明显差异 ,B组纤维包膜中光镜下发现外渗的凝胶颗粒。术后与术前 4组大鼠间血液中有机硅的浓度比较 ,差异均无显著性。结论 :完整的硅凝胶假体、人为刺破外壳的硅凝胶假体与生理盐水充注型假体的组织学反应无明显差异 ,外渗的凝胶局限在纤维包膜的内层 ,也不会随血液或淋巴到机体其他部位。     

Capsular Management in Direct Anterior Total Hip Arthroplasty: A Randomized,Single-Blind,Controlled Trial

BackgroundThe direct anterior approach (DAA) is a popular approach to total hip arthroplasty (THA). Unlike the posterior approach, the importance of anterior capsular management is unknown. This randomized controlled trial compares capsular repair versus capsulectomy.MethodsThis single-surgeon, single-blinded, parallel-group randomized controlled trial occurred between 2013 and 2016. Patients undergoing unilateral, primary THA for osteoarthritis consented to undergo blinded, simple randomization to anterior capsulotomy with repair or anterior capsulectomy. Primary outcome measures included hip range of motion, hip flexion strength, and pain with seated hip flexion. Secondary outcome measures included surgical time, estimated blood loss, postoperative complications, and hip disability and osteoarthritis outcome score. Data were prospectively collected intraoperatively, six weeks, six months, an average of over 5 years postoperatively.ResultsNinety-eight patients were ultimately enrolled in the trial; 50 received capsulectomy and 48 received capsulotomy. No significant differences were seen in preoperative demographics or in primary or secondary outcomes during this study. No difference was seen in pain at final follow-up at average > 5 years postoperatively.ConclusionThis study demonstrates that capsular management in DAA THA does not affect postoperative pain or range of motion. The anterior capsule’s role in prosthetic stability after DAA THA remains uncertain, but it does not currently appear that repair provides benefit and may lead to increased surgical time and blood loss. As such, capsular management in DAA THA is at surgeon discretion.     

The parabiliary venous system

Summary The parabiliary venous system originates from the pancreatico-duodenal and pyloro-duodenal veins, runs along the common bile-duct and the hepatic artery, and divides in the liver hilum into a venous network within the hilar plate. Embryologically, this system, apparently independent of the portal vein, develops together with the bile-ducts and the hepatic artery: these three structures are within the substance of the vasculo-biliary sheaths, and the whole complex invades the liver well after the distribution of the portal vein has been established. It should be pointed out that segments I and IV also appear rather late. Seventy-four specemins with injection of the system have been studied. The hilar plexus sends branches to the veins of the segments adjacent to the hilum. Some vessels directly supply the inferior surface of the quadrate lobe or the caudate lobe, or the left lobe. In 46.50% of specemins, part of the cystic veins are anastomosed with the Parabiliary system.

---

Le système veineux parabiliaire

Résumé Le système veineux parabiliaire prend origine dans les veines pancréatico-duodénales et pyloro-duodénales, monte le long de la voie biliaire et l'artère hépatique, et se termine dans le hile dans un lascis veineux situé dans la plaque hilaire. Embryologiquement il semble étranger à la formation de la veine porte, se constitue en même temps que les canaux biliaires et les artères intra-hépatiques: ces trois éléments sont situés dans la texture même des enveloppes vasculo-biliaires, et le tout envahit le foie bien après la pénétration de la veine porte. L'étude porte sur 74 foies dans lesquels le système s'est trouvé injecté. Le plexus hilaire envoie des collatérales qui se jettent dans les veines des segments adjacents au hile. Mais certaines branches irriguent directement la face inférieure du lobe carré, ou le lobe gauche. Dans 46,50% des cas, une partie des veines cystiques se jettent dans ce système.

     

术苓健脾胶囊对TNBS诱导的大鼠实验性结肠炎的作用及机制

探讨术苓健脾胶囊（术苓）对2,4,6-三硝基苯磺酸（TNBS）诱导的大鼠实验性结肠炎的作用及其机制。采用2.5%TNBS灌肠制备大鼠实验性结肠炎模型。将大鼠随机分为正常组、模型组、肠炎宁（180 mg/kg）组以及术苓低剂量（40 mg/kg）、高剂量（120 mg/kg）组。造模后药物治疗7 d后处死大鼠。其间每日记录大鼠体重,观察大鼠疾病活动状态。实验结束后,取结肠组织进行HE病理学分析、检测结肠组织中髓过氧化物酶（MPO）酶活、诱导型一氧化氮合酶（iNOS）、炎性细胞因子（IL-6、IL-1β、IFN-γ、IL-10）及紧密连接蛋白（occludin、ZO-1）的表达水平,并检测血清中炎性细胞因子（IL-6、IL-1β）的含量。结果表明,与模型组相比,术苓给药显著缓解了TNBS造模引起的体重下降、疾病活动指数（DAI）升高,缓解了结肠组织的缩短、水肿以及病理学损伤,减少了炎性细胞浸润、隐窝的破坏与杯状细胞的丢失,降低了结肠组织MPO酶活性、iNOS与炎性细胞因子的水平,增加了结肠紧密连接蛋白的表达,同时降低了血清中的炎性因子的含量。结果表明,术苓通过降低炎性因子水平,增加肠道紧密...     

双诺希胶囊对实验性高脂血症的影响

目的　验证双诺希胶囊 ( SHNX)对高脂血症大鼠血脂的影响 .方法　用高脂饲料喂饲大鼠建立高脂血症模型 ;随机分为 6组 ,即正常对照组、高脂模型组、SHNX大剂量组( SHNXH1.2 0 0 g· kg- 1 )、SHNX中剂量组 ( SHNXM0 .60 0 g· kg- 1 )、SHNX小剂量组 ( SHNXL 0 .3 0 0 g· kg- 1 )和安妥明组 ( Clofibrate) ,连续喂饲并灌胃给药 3 0 d后 ,观察 SHNX对高脂血症大鼠血脂含量的影响 .结果　 SHNX能明显降低血清总胆固醇 ( TC)、三酰甘油 ( TG)含量 ,亦能明显提高血清高密度脂蛋白亚组分 胆固醇 ( HDL2 - C)及高密度脂蛋白胆固醇 ( HDL - C)的含量 .结论　 SHNX对血脂紊乱大鼠有明显的治疗效果 .